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Introduction: Type 2 diabetes mellitus (T2DM) is an expanding global health 
problem, closely linked to the epidemic of obesity. The incidence of diabetes is 
increasing because of aging, changing ethnic mix of the population and worsening 
obesity. Glibenclamide is used for the treatment of patients with type II diabetes 
mellitus. Some patients respond well to this therapy while others need to use higher 
doses along with other medications. Since polymorphisms in ACE gene has been 
associated with type 2 diabetes mellitus, in the present study we investigated the 
association of insertion/deletion mutations of this gene with the effectiveness of 
Glibenclamide in treating Iranian type 2 diabetic patients. 
 
Methods and Results: In this experimental study, blood samples from type II 
diabetic patients were collected (n=99) and their genomic DNA was isolated. 
Specific primers for the detection of insertion/deletion mutation were used and 
polymerase chain reactions (PCR) were conducted using specific thermal cycles. 
The amplified DNA samples were detected by electrophoresis of these samples on a 
0.7% agarose gel. Statistical analysis of the obtained data was performed using t-test 
and chi-square test. A total of 99 patients were enrolled to the study. The frequency 
distribution of DD, ID, and II polymorphisms were 72%, 20%, and 8%, respectively. 
There were no differences among genotypic groups (P = 0.146). In terms of 
cholesterol, there was a significant difference between DD and DI (P = 0.012). There 
was a significant difference between the two DD and II genotypes in terms of 
creatinine (P = 0.034) 
 
Conclusions: Although the results of our study indicated no association of ACE I/D 
polymorphisms and Effectiveness of Glibenclamide therapy, DD genotype may play 
a role on effectiveness of Glibenclamide Therapy. 
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